Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Cole

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Pediatric Blood & Cancer|March 22, 2022
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001Uma H Athale, Yael Flamand, Traci Blonquist, et al.
British Journal of Haematology|August 14, 2024
Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemiaQianqian Zhu, Ram Nambiar, Emily Schultz, et al.
British Journal of Haematology|April 3, 2015
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group studyTerzah M Horton, Richard A Drachtman, Lu Chen, et al.
Nature Cancer|May 25, 2026
Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activityAlan Y L Wong, Jacob W Myers, Gyan Prakash, et al.
Blood Advances|March 7, 2018
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemiaThai Hoa Tran, Marian H Harris, Jonathan V Nguyen, et al.
Blood Advances|June 27, 2018
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001Lynda M Vrooman, Traci M Blonquist, Marian H Harris, et al.
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Blood Advances|December 21, 2021
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001Thai Hoa Tran, Sylvie Langlois, Caroline Meloche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2021
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001Lynda M Vrooman, Traci M Blonquist, Kristen E Stevenson, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALLKristen M O'Dwyer, Lena E Winestone, Matthew C Cheung, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Pediatric Blood & Cancer|March 22, 2022
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001Uma H Athale, Yael Flamand, Traci Blonquist, et al.
British Journal of Haematology|August 14, 2024
Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemiaQianqian Zhu, Ram Nambiar, Emily Schultz, et al.
British Journal of Haematology|April 3, 2015
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group studyTerzah M Horton, Richard A Drachtman, Lu Chen, et al.
Nature Cancer|May 25, 2026
Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activityAlan Y L Wong, Jacob W Myers, Gyan Prakash, et al.
Blood Advances|March 7, 2018
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemiaThai Hoa Tran, Marian H Harris, Jonathan V Nguyen, et al.
Blood Advances|June 27, 2018
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001Lynda M Vrooman, Traci M Blonquist, Marian H Harris, et al.
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Blood Advances|December 21, 2021
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001Thai Hoa Tran, Sylvie Langlois, Caroline Meloche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2021
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001Lynda M Vrooman, Traci M Blonquist, Kristen E Stevenson, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALLKristen M O'Dwyer, Lena E Winestone, Matthew C Cheung, et al.
Pageof 11